Received Jul 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Received a first dose in September 2023 and 2nd dose in October 2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). In OCT-2023, the patient received the 2nd dose of Shingrix. In OCT-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Received a first dose in September 2023 and 2nd dose in October 2023). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 15-JUL-2025 The pharmacist reported that a patient received a first dose of the Shingrix vaccine and received the second dose a little bit early in October 2023. She wanted to know if that was a problem and asked if she needs to get another dose or what was the advice if somebody received the second dose of Shingrix too early. The patient received 2nd dose of Shingrix earlier than recommended interval, which led to shortening of vaccination schedule.
Shingrix